How T Cell Engagers Could Provide a Treatment Option for Immunologically Cold or Unresponsive Tumors

Judd Englert, MD, PhD, is currently an Executive Medical Director for Oncology at Amgen. In this role, he is responsible for the early phase development of multiple assets and serves as the global product team lead for Xaluritamig, an investigational STEAP1-targeted T-cell engager for prostate cancer. Prior to this, Dr Englert was the SVP of Clinical Research and Development at Cyteir Therapeutics where he led the clinical organization and oversaw the development of an MCT-1 inhibitor as well as earlier pipeline programs. Before this, Dr Englert was a Senior Director at UPMC Enterprises, where he led the evaluation and diligence for investment into biotechnology companies across all therapeutic areas. Dr Englert started his industry career at MedImmune in the early phase oncology group leading and developing numerous immunotherapy and ADC programs for solid tumors. He received his MD and PhD from the University of Pittsburgh, completed his internal medicine residency at Brigham and Women’s Hospital and a fellowship in medical oncology at Johns Hopkins Hospital where his post-doctoral studies on glutamine inhibition in cancer led to the formation of a biotech company.